FDA, IMI, and Patient Advocates to Present at CDISC 2012 International Interchange Formal Launch of CFAST - Collaboration between C-Path and CDISC

The Clinical Data Interchange Standards Consortium (CDISC) and Critical Path Institute (C-Path) announce the launch of the Coalition For Accelerating Standards and Therapies (CFAST), a follow-up to the partnership agreement signed earlier this year. The official launch of CFAST will take place at the CDISC 2012 International Interchange in Baltimore, Maryland (24-26 October 2012).

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend

Austin, TX (PRWEB) September 12, 2012

The Clinical Data Interchange Standards Consortium (CDISC) and Critical Path Institute (C-Path) announce the launch of the Coalition For Accelerating Standards and Therapies (CFAST), a follow-up to the partnership agreement signed earlier this year. The official launch of CFAST will take place at the CDISC 2012 International Interchange in Baltimore, Maryland (24-26 October 2012).

CFAST is an initiative to accelerate clinical research and medical product development by facilitating the creation and maintenance of data standards, tools, and methods for conducting research in therapeutic areas important to public health. To date, CDISC has either released draft or provisional standards packages covering five different disease areas: Parkinson’s, Alzheimer’s, Tuberculosis, Virology and Pain. Upcoming releases will include therapeutic area standards packages for Polycystic Kidney Disease, Cardiovascular Disease and Schizophrenia.

Dr. Carolyn Compton, C-Path President and CEO, states, “CFAST will serve as a strong partner assisting the FDA in meeting their PDUFA V performance goals of ‘improving efficiency of human drug review through required data submissions standardization.’ We are optimistic that this partnership will truly make a difference in the review process.”

Paula Brown Stafford, Chair of the CDISC Board says, “The CDISC Board of Directors encourages attendance at the Interchange by leaders in the healthcare and technology fields. We welcome participation to help inform patient care and safety through higher quality medical research.”

Interchange attendees can participate in discussions with a number of thought leaders who are actively working to improve public health. Keynote speakers include Dr. Janet Woodcock of the U.S. Food and Drug Administration (FDA) and Ann Martin of Europe’s Innovative Medicines Initiative (IMI). Patient advocacy groups with participating representation include One Mind for Research, DataSphere (a biopharma data sharing initiative), the Vradenburg Foundation and the Michael J. Fox Foundation. Other participating organizations are the Japan Translational Research Informatics Institute, the U.S. National Cancer Institute, the Texas eHealth Alliance, Duke University and the University of Rochester.

Registration for the CDISC 2012 International Interchange is open. For more details, visit http://www.cdisc.org/interchange. There are also educational course openings and related meetings.

The CDISC 2012 International Interchange is funded in large part through the generous contributions of member companies. Sponsors of this year’s International Interchange include Digital Infuzion, SAS, Octagon Research Solutions, Percept Pharma, Edetek and Pinnacle 21. Sponsorship opportunities remain available. See http://www.cdisc.org/interchange.

ABOUT CDISC
CDISC is a 501(c)(3) global non-profit charitable organization, with approximately 300 supporting member organizations from across the global clinical research and healthcare arenas. Through the efforts of volunteers around the globe, CDISC catalyzes productive collaboration to develop industry-wide data standards enabling the harmonization of clinical data and streamlining research processes from protocol through analysis and reporting, including the use of electronic health records to facilitate the collection of high quality research data. The CDISC standards and innovations can substantially decrease the time and cost of medical research and improve quality, thus contributing to the faster development of safer and more effective medical products and a learning healthcare system. The CDISC Vision is to inform patient care and safety through higher quality medical research. CDISC standards are freely available; for more information on CDISC, please visit http://www.cdisc.org.

ABOUT CRITICAL PATH INSTITUTE (C-PATH): Established in 2005 as a non-profit organization, C-Path was formed with public and private philanthropic support from the University of Arizona, the US Food and Drug Administration (FDA), and the Tucson community. Additional funding has been provided by Science Foundation Arizona (SFAz). C-Path is committed to improving human health and well-being by developing new technologies and methods to accelerate the development and review of medical products. An international leader in forming collaborations around this mission, C-Path has established global, public-private partnerships that include more than 1,000 scientists from government regulatory agencies, academia, patient advocacy organizations, and 41 major pharmaceutical companies. C-Path has headquarters in Tucson, AZ and an office in Rockville, MD. For more information, visit http://www.c-path.org and follow us on Facebook.


Contact